<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02816710</url>
  </required_header>
  <id_info>
    <org_study_id>2016062501</org_study_id>
    <nct_id>NCT02816710</nct_id>
  </id_info>
  <brief_title>Conbercept Injection in Treatment of Vitreous Hemorrhage</brief_title>
  <official_title>Different Conbercept Injection Methods in Treatment of Vitreous Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy of different intravitreal Conbercept injection therapy in the treatment
      of vitreous hemorrhage (VH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Vitreous Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Conbercept 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conberecep injection before vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conbercept 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First Conberecep injection before vitrectomy and second at the end of operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conbercept 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conberecep injection at the end of vitrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conbercept</intervention_name>
    <arm_group_label>Conbercept 1</arm_group_label>
    <arm_group_label>Conbercept 2</arm_group_label>
    <arm_group_label>Conbercept 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ageâ‰¥18 years

          -  VH obscuring the disc and vessels for more than 14 days and no evidence of retinal
             detachment and never treated with intravitreal injection

        Exclusion Criteria:

          -  Previous history of vitrectomy

          -  Previous intravitreal any drugs injection in either eye

          -  Pregnancy or current oral contraceptive intake usage of clopidogrel bisulfate or
             coumadin

          -  Uncontrolled hypertension and cardiac disease

          -  Uncontrolled renal or liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi Shen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xi Shen, PhD</last_name>
    <phone>+86 136-2167-7680</phone>
    <email>carl_shen2005@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Shen, PhD</last_name>
      <phone>+86 136-2167-7680</phone>
      <email>carl_shen2005@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2016</study_first_submitted>
  <study_first_submitted_qc>June 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>June 25, 2016</last_update_submitted>
  <last_update_submitted_qc>June 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Xi Shen</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Vitreous Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

